Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Maxim Group Downgrades Biotricity to Hold

Maxim Group analyst Allen Klee downgrades Biotricity (NASDAQ:BTCY) from Buy to Hold.
byBenzinga Newsdesk
July 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Maxim Group analyst Allen Klee downgrades Biotricity (NASDAQ:BTCY) from Buy to Hold.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Wiliam Blair Issues Note Regarding New Guidelines On A ImmunoGen Drug, The National Comprehensive Cancer Network Just Released New Guideline Which Include Elahere, As A Preferred Regimen

By Benzinga Newsdesk
December 28, 1:14 PM
The National Comprehensive Cancer Network (NCCN) just released new guidelines (Version 1.2023) for the treatment of ovarian cancer, which include Elahere (IMGN drug) as a preferred regimen.  This comes as a particular surprise to the upside, since it occurred faster than our (and likely the Street’s) expectations. It is our view that

IMGN